Skip to main content
Support Quality Journalism.
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just
$1.99
per week
for first 24 weeks
Enjoy unlimited digital access
START TODAY
Get full access to globeandmail.com
Just $1.99 per week
for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
The Globe and Mail
Member Benefits
Subscribe
Subscribe
Register
Log in
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
AdChoices
Canada
World
Business
Investing
Opinion
Politics
Sports
Life
Arts
Drive
Real Estate
Watchlist
Search
Search
Quick links
Horoscopes
Puzzles
Member Benefits
Newsletters
Globe Shop
Investigations
Death Notices (Legacy.com)
Reader services
Subscribe
Following
Subscriptions
Settings
Customer Help
Contact us
Log in
Log out
Biotechnology
Follow
Latest
advisor etfs
Why the nascent psychedelics industry is getting investors’ attention
Globe Advisor content
March 2
Updated
report on business
First TSX-only biotech IPO in 18 years set for next week as Eupraxia closes books on $41-million offering
March 1
Updated
report on business
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding
February 10
Updated
report on business
TMX CEO aims to encourage small biotech companies to list in Canada
February 9
Updated
report on business
RBC taps into biotech surge, investing in new Lumira venture fund
February 1
Updated
report on business
Vancouver’s Khosrowshahi family to launch US$400-million pharma IPO, capitalizing on biotech craze
January 25
Updated
More Stories Below Advertisement
report on business
Rare milestone approaches for Canadian biotech sector as Aurinia awaits FDA OK to sell new drug
January 17
Updated
report on business
AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO
January 7
Updated
opinion
What Canada needs to do to build a world-class biotech sector
Roberto Bellini
December 23
Updated
report on business
AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million
December 16
Updated
number cruncher
Which of these top 10 Canadian biotech stocks are undervalued?
December 14
Updated
international business
AstraZeneca shares fall as investors react to $39-billion Alexion acquisition
December 14
Updated
international business
AstraZeneca to buy U.S. drugmaker Alexion for $39-billion to expand in immunology
December 12
Updated
report on business
Vancouver’s AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech
December 7
Updated
investment ideas
Cowen’s CEO sees gains in biotech, helped by easier access to cash
December 2
Updated
report on business
Booming Canadian biotech sector on track for record year after raising $1-billion in venture capital so far in 2020
November 26
Updated
More Stories Below Advertisement
report on business
Peter Thiel joins board of B.C. antibody therapy developer AbCellera in advance of expected IPO
November 19
Updated
report on business
Canada’s Pascal Biosciences partners with U.S. firm to test cannabis-based cancer therapy
September 14
Updated
report on business
Antibody therapy developer AbCellera hires banks for U.S. IPO, sources day
September 11
Updated
international business
Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal
August 17
Updated
international business
CureVac doesn’t rule out accelerated approval for COVID-19 vaccine
August 16
Updated
advisor mutual funds
Active management finds niche in post-pandemic market
Globe Advisor content
August 4
Updated
report on business
Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall
July 27
Updated
stars and dogs
The Globe’s stars and dogs for the week
July 17
Updated
letters
July 9: ‘The government of the people, by Justin Trudeau, for the people.’ Readers take a closer look at the WE Charity contract, plus other letters to the editor
July 9
Updated
streetwise newsletter
Streetwise newsletter: Best reads of the week
July 3
Updated
report on business
Biotech blind spot: How Canada’s big investors missed the boom happening right now
July 3
Updated
inside the market
Top Canadian biotech investor on the firms most likely to turn COVID-19 drug trials into treatments and when a vaccine may arrive
July 3
Updated
stars and dogs
The Globe’s stars and dogs for the week
July 3
Updated
science
BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial
July 1
Updated
european business
Temasek-led investor group makes $250-million vaccine bet on Germany’s BioNTech
June 29
Updated
technology
Hamilton biotech Fusion sets IPO price at $17 a share for Friday debut on Nasdaq
June 25
Updated
streetwise newsletter
Streetwise newsletter: Fusion Pharmaceuticals looks to raise more than $150-million as it launches IPO
June 22
Updated
report on business
Repare soars to largest ever IPO of a Canadian biotech firm in Nasdaq debut
June 19
Updated
report on business
Repare Therapeutics seeks to raise up to US$152-million in Nasdaq share offering
June 15
Updated
View More Stories
To view this site properly, enable cookies in your browser. Read our
privacy policy
to learn more.
How to enable cookies